June 22, 2020 / 9:35 AM / 22 days ago

BRIEF-Aridis Reports Ar-501 Clinical Data Positive Safety Data In Healthy Subjects Of A Phase 1/2A Clinical Trial

June 22 (Reuters) - Aridis Pharmaceuticals Inc:

* ARIDIS REPORTS AR-501 CLINICAL DATA: POSITIVE SAFETY DATA IN HEALTHY SUBJECTS OF A PHASE 1/2A CLINICAL TRIAL

* ARIDIS PHARMACEUTICALS INC - AR-501 AEROSOLS WERE WELL TOLERATED

* ARIDIS PHARMACEUTICALS - “LOOK FORWARD TO ADVANCING TO PHASE 2A STAGE OF STUDY EVALUATING ADULT CYSTIC FIBROSIS PATIENTS, WITH RESULTS EXPECTED IN 2H 2021.”

* ARIDIS PHARMACEUTICALS - NO SERIOUS ADVERSE EVENTS , NO GRADE 3 OR GRADE 4 ADVERSE EVENTS REPORTED OVER 28 DAY STUDY PERIOD FOR SINGLE ASCENDING DOSE COHORT Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below